Tuesday, October 25, 2011
PharmaGap Inc., of Ottawa, said it has chosen ovarian cancer as its target for clinical development of GAP-107B8. The company expects to apply for the first Phase I trial by the end of next year. GAP-107B8, a peptide that has been shown to be highly cytotoxic to numerous cancer types, was being considered for bladder and ovarian cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.